F

Fortrea Holdings Inc
NASDAQ:FTRE

Watchlist Manager
Fortrea Holdings Inc
NASDAQ:FTRE
Watchlist
Price: 20.69 USD -0.96% Market Closed
Market Cap: 1.9B USD
Have any thoughts about
Fortrea Holdings Inc?
Write Note

Fortrea Holdings Inc
Non-Reccuring Items

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Fortrea Holdings Inc
Non-Reccuring Items Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Non-Reccuring Items CAGR 3Y CAGR 5Y CAGR 10Y
F
Fortrea Holdings Inc
NASDAQ:FTRE
Non-Reccuring Items
-$24.3m
CAGR 3-Years
61%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Thermo Fisher Scientific Inc
NYSE:TMO
Non-Reccuring Items
-$231m
CAGR 3-Years
-9%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Danaher Corp
NYSE:DHR
Non-Reccuring Items
-$222m
CAGR 3-Years
-114%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Mettler-Toledo International Inc
NYSE:MTD
Non-Reccuring Items
-$30.7m
CAGR 3-Years
-52%
CAGR 5-Years
N/A
CAGR 10-Years
-11%
Agilent Technologies Inc
NYSE:A
Non-Reccuring Items
-$74m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
IQVIA Holdings Inc
NYSE:IQV
Non-Reccuring Items
-$94m
CAGR 3-Years
-30%
CAGR 5-Years
-6%
CAGR 10-Years
-26%
No Stocks Found

Fortrea Holdings Inc
Glance View

Market Cap
1.9B USD
Industry
Life Sciences Tools & Services

Fortrea Holdings, Inc. engages in the provision of clinical development and commercialization services. The company is headquartered in Durham, North Carolina and currently employs 19,000 full-time employees. The company went IPO on 2023-06-16. The firm is a provider of comprehensive Phase I through IV clinical trial management, clinical pharmacology, patient access solutions and other enabling services. The Company’s segments include Clinical Services and Enabling Services. The Company’s global solutions include Clinical Development, Clinical Pharmacology, Drug Development Consulting Services, Device and Diagnostic Development, and Full and Functional Service Provider Models, among others. Its Clinical Development solutions include Early: Phase I/II a, Late: Phase II b/III, Real-World Evidence and Post-Approval Studies, Decentralized Clinical Trials, Data Analysis and Reporting, Clinical Trial Project Management and Monitoring, and Patient Safety and Pharmacovigilance. By therapeutic or specialty areas, it has scientific expertise in cardiovascular, cell and gene therapies, dermatology, diabetes and endocrinology, hepatology, infectious disease, and others.

FTRE Intrinsic Value
32.14 USD
Undervaluation 36%
Intrinsic Value
Price
F

See Also

What is Fortrea Holdings Inc's Non-Reccuring Items?
Non-Reccuring Items
-24.3m USD

Based on the financial report for Dec 31, 2023, Fortrea Holdings Inc's Non-Reccuring Items amounts to -24.3m USD.

What is Fortrea Holdings Inc's Non-Reccuring Items growth rate?
Non-Reccuring Items CAGR 3Y
61%

Over the last year, the Non-Reccuring Items growth was 40%. The average annual Non-Reccuring Items growth rates for Fortrea Holdings Inc have been 61% over the past three years .

Back to Top